Drug Profile

Research programme: MAIT-engaging T-cell directing bispecific antibodies - Biomunex Pharmaceuticals/Curie Institute

Latest Information Update: 19 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Curie Institute
Developer Biomunex Pharmaceuticals
Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
Mechanism of Action Immunologic cytotoxicity; T-lymphocyte subset stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

07 Nov 2025 Biomunex plans a clinical trial for Solid tumours (Parenteral)
25 Apr 2025 Pharmacodynamics data from preclinical trial presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
04 Mar 2024 Biomunex Pharmaceuticals enters into an exclusive licensing and exploitation agreement with Curie Institute for the development of MAIT Engagers

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com